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honor a scientist who, over the previ-
ous five years, has made significant 
contributions to the understanding of 
the structure and function of the skin. 
This year, Peter Elias (University of 
California, San Francisco) presented 
his work elucidating the nature of the 
mammalian epidermal permeability 
barrier. Building on research begun in 
1974, Dr. Elias described nuclear hor-
mone receptors—peroxisome prolifer-
ator–activated receptors (PPARs) and 
liver X receptors (LXRs)—that function 
as liposensors to regulate barrier func-
tion. Among the desirable effects of 
such PPAR/LXR ligands in models of 
inflammatory dermatoses are decreases 
in proliferation and inflammation along 
with increased differentiation, lipid 
synthesis, barrier function, and antimi-
crobial peptide expression. Although 
it is known that the stratum corneum 
functions to protect the organism by 
providing a permeability barrier and 
antimicrobial defense, recent evidence 
indicates that these functions appear to 
be not only coregulated but also inter-
related. Both functions share a com-
mon delivery system and are affected 
by acidification, cohesive structure, 
lamellar bilayers that block entry to the 
body, and decreased water content. 
Furthermore, Dr. Elias indicated that 
differences in barrier recovery kinet-
ics result from psychological stress and 
pigmentation.
As a result of the finding that more 
than 50% of mammalian transcripts 
have no protein-coding potential, many 
investigators have shifted their focus to 
In May 2011, the 71st Annual Meeting 
of the Society for Investigative 
Dermatology (SID) was held in Phoenix, 
Arizona.* The overriding goal of the SID 
is to advance and promote the sciences 
relevant to skin health and disease. 
With an international group of approxi-
mately 1,500 researchers in attendance, 
this scientific meeting offered an oppor-
tunity for clinicians and researchers to 
exchange knowledge and ideas in the 
fields of dermatology and cutaneous 
biology for the purpose of advancing 
this goal. The scientific program of 
the 2011 Annual Meeting spanned 
a wide variety of topics, including 
cell differentiation and development, 
immunology, skin disease etiology and 
treatment development, and cancer. 
These proceedings, which were based 
on the full recorded presentations 
from the meeting, highlight the vari-
ety of cutting-edge research performed 
by this international community of 
investigators. Unfortunately, space limi-
t ations precluded a description of every 
presentation from the meeting, which 
included nearly 900 oral and poster 
presentations; thus, the subsequent dis-
cussion highlights the Plenary Sessions, 
State-of-the-Art Plenary Lectures, and 
named lectures. Please refer to the 
full meeting program and abstracts 
online for further details (http://sidnet.
org/Admin/UserFiles/File/FINAL%20
2011%20Meeting%20Program.pdf).
Cell differentiation and development
The Albert M. Kligman/Phillip Frost 
Leadership Lecture was established to 
Scientific Highlights from the 71st Annual Meeting  
of the Society for Investigative Dermatology
Heather Yarnall Schultz1
Journal of Investigative Dermatology (2011) 131, 1963–1967. doi:10.1038/jid.2011.244
understanding the role of these RNAs, 
which include the long noncoding 
RNAs (lncRNAs), in differentiation and 
development. Markus Kretz (Stanford 
University, Palo Alto, CA) presented 
results gleaned from full-transcriptome 
RNA sequencing. One such lncRNA, 
terminal differentiation-induced ncRNA 
(TINCR), is essential for epidermal dif-
ferentiation. Indeed, TINCR is induced 
during epidermal differentiation and 
is required for induction of genes that 
mediate protein and lipid components 
of the epidermal barrier. In addition, 
a high-throughput screen of 9,400 
proteins identified Staufen1 protein 
as a binding partner for TINCR, and, 
functionally, loss of Staufen1 recapitu-
lates TINCR deficiency–induced lack 
of terminal differentiation, confirm-
ing the biological relevance of this 
interaction. Additionally, Carolyn Lee 
(Stanford University) described the role 
of anti differentiation ncRNA (ANCR) 
in maintenance of the epidermal pro-
genitor state. ANCR is downregulated 
during progenitor differentiation in a 
variety of tissues. Depletion of ANCR 
in keratinocytes results in spontaneous 
differentiation and can induce ectopic 
expression of differentiation genes in 
the lower spinous and basal layers of 
the epidermis. Together, these presenta-
tions emphasized the critical nature of 
these ncRNAs in epidermal differentia-
tion and development.
In another plenary presentation, 
Mandy Shu Shien Chin (SUNY Buffalo, 
NY) described the novel mechanism by 
which Ets1, a transcription factor that 
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is overexpressed in cancers associated 
with poor prognosis, such as poorly dif-
ferentiated squamous cell carcinoma 
(SCC), regulates the skin differentiation 
program. Overexpression of Ets1 
in mice results in a severe skin 
phenotype marked by hair loss, hyper-
proliferation, disrupted differentiation, 
increased angiogenesis, and infiltra-
tion by myeloid cells. In addition, Ets1 
overexpression derails the terminal 
differentiation program of the inter-
follicular (IF) epidermis via suppression 
of Notch activity through direct regu-
lation of the Notch antagonist ΔNp63.
Because alopecia is a common prob-
lem that results from genetic alterations, 
as a symptom of other diseases, and as 
a side effect of chemotherapy, skin biol-
ogists seek to understand the factors 
governing hair cycling and hair follicle 
(HF) development. Liang Liu (Columbia 
University, New York, NY) described 
evidence that hairless is a novel his-
tone demethylase that removes methyl 
groups at H3K9me1 and H3K9me2 
on such target genes as Wise, Caspase 
14, and Mxi1. The hairless gene is 
expressed during HF cycling at the ana-
gen-to-catagen transition and may play 
an important role in regulating tumori-
genesis. In addition, stem cells have 
been a focus of study for understanding 
tissue regeneration as well as for the 
development of novel cell therapies. 
Valerie Horsley (Yale University, New 
Haven, CT) presented her investigations 
to elucidate the intrinsic and extrinsic 
factors that control follicular stem cells. 
Although considerable evidence indi-
cates that bulge cells are responsible 
for the regeneration of the HF, these 
cells are present in both haired and 
bald human scalp, suggesting that vari-
ous signals are essential for control of 
the activity of these cells. The nuclear 
factor of activated T cells is one intrin-
sic factor that is necessary for delayed 
telogen and thus for regulation of stem 
cell activity. Furthermore, studies using 
three different mouse models revealed 
that adipocyte lineage cells establish a 
niche for follicular cells and serve as a 
source of extrinsic control of the hair 
cycle. In another plenary presentation, 
Jiang Chen (University of Colorado, 
Anschutz Medical Campus, Aurora) 
described epidermal-specific disruption 
of Intu, a tissue-specific planar cell 
polarity effector gene. Apparently, loss 
of Intu prohibits HF differentiation via 
direct blockade of primary cilia forma-
tion in epidermal keratinocytes.
In addition to the excellent lineup 
of presentations from dermatologists 
and cutaneous biologists, the SID also 
honors a leading medical scholar out-
side the field of cutaneous biology with 
an opportunity to deliver the Herman 
Beerman Lecture in order to expose the 
investigators in attendance to exciting 
scientific advancements in other fields. 
This year, Jennifer Lippincott-Schwartz 
(NIH, Bethesda, MD) presented her 
work on superresolution imaging with 
photoactivatable fluorescent proteins. 
Her research employs live cell imaging 
approaches to analyze the spatiotempo-
ral behavior and dynamic interactions 
of molecules in cells in order to explore 
protein transport and the cytoskeleton, 
organelle assembly and disassembly, 
and generation of cell polarity.
immunology
Inflammatory mediators play a role 
in the pathogenesis of many skin 
diseases and cancers; thus, understand-
ing the biology of the immuno logical 
response is paramount to deciphering 
disease mechanisms and developing 
novel therapeutic strategies. Reflecting 
this, numerous presentations at the 
SID Annual Meeting focused on the 
role of inflammation, skin-resident 
immunocytes, and cytokines in dis-
ease processes. In the Eugene M. 
Farber Endowed Lecture, which hon-
ors an investigator whose work is rel-
evant to expanding our insights into 
the pathophysiology and treatment of 
psoriasis, Kevin Cooper (Case Western 
Reserve University, Cleveland, OH) 
described his research on the iden-
tification of the immunologic target 
in psoriasis. To date, several mecha-
nisms, including susceptibility genes, 
epigenetic factors, innate sensors, 
and adaptive immunity players, have 
been implicated in the patho genesis 
of psoriasis; however, quite a few of 
the psoriasis drugs that are currently in 
development target players critical in T 
cell development, such as the JAK/STAT 
pathway, interleukin (IL)-23, IL-17, 
IL-22, IL-17 receptor (IL-17R), and 
interferon (IFN)-γ. For example, IL-6 is 
expressed on endothelial cells and den-
dritic cells (DCs) in lesional skin in pso-
riasis patients. An increase in IL-6 and 
IL-21, which signals through the JAK/
STAT pathway, results in release from 
regulatory T cell (Treg) suppression and 
subsequent proliferation, whereas an 
increase in IFN-γ restores this regula-
tion by Tregs. Thus, T cells integrate dif-
ferential inhibitory or activating signals 
from their antigen-presenting cells to 
influence the immune reaction. This 
complex regulation, which is beginning 
to be elucidated, offers potential tar-
gets for the treatment of psoriasis. For 
example, targeting IL-6 signaling may 
rebalance the activity of the Treg and T 
effector cell populations to effectively 
treat psoriasis. In a related talk, Takuya 
Furuhashi (Nagoya City University, 
Japan) presented the results of his inves-
tigations of the molecular mechanisms 
behind bath-psoralen UVA and narrow-
band UVB therapies for the treatment 
of psoriasis. Both therapies induced 
circulating Treg populations concomi-
tantly with a decrease in Psoriasis Area 
and Severity Index score. In addition, 
phototherapy decreased the number 
of circulating T helper type 17 (Th17) 
cells. Therefore, phototherapy may 
serve to correct the imbalance between 
Th17 and Treg populations in psoriasis 
patients via IL-6 suppression.
The immunologic cellular players are 
exquisitely regulated during the immune 
response. Understanding the control of 
these populations is critical for under-
standing skin biology and pathology. 
Casey Weaver (University of Alabama, 
Birmingham) delivered the 2011 Julius 
Stone Lecture, which is intended to 
promote the advancement of research 
in immunology as it relates to the skin 
and skin diseases. Weaver presented 
his insight into the mechanism of T-cell 
development in the immune response 
with specific emphasis on the role of 
IL-17- and IFN-γ-producing CD4+ T cells 
in infection and psoriasis. Daniel Kaplan 
(University of Minnesota, Minneapolis) 
described a model for skin-resident DC 
function based on the results of studies 
with huLangerin-DTA mice. Basically, 
three subsets of DCs—Langerin-postive 
dermal DCs (dDCs), Langerin-negative 
dDCs, and Langerhans cells (LCs)—
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reside in the skin. LCs are necessary and 
sufficient for the generation of antigen-
specific Th17 cells but not for generation 
of cytotoxic T lymphocytes, whereas 
Langerin-positive dDCs are required for 
cytotoxic T lymphocytes and Th1 cells. 
These Langerin-positive dDCs inhibit 
the development of the Th17 response. 
In the absence of Langerin expression, 
Langerin-negative dDCs promote this 
Th17 response. Thus, these three DC 
subsets are not redundant; in fact, these 
cell types produce distinct and oppos-
ing antigen-specific T-cell responses.
To elucidate the immune response 
to pathogens in the skin or to tumors, 
the role of cytokines in these processes 
must also be uncovered. These immuno-
modulatory molecules are important 
in determining the type and extent of 
the immune reaction. Thomas Kupper 
(Brigham and Women’s Hospital, 
Boston, MA) presented his work on 
the role of IL-9 as a potent mediator of 
antitumor immunity. In mice lacking 
the transcription factor RAR–related 
orphan receptor-γ (ROR-γ), which con-
trols Th17 development, melanoma 
growth is inhibited concurrent with 
alteration of IL-17 and abundant IL-9 
production. Blockade of IL-9 inhibits 
tumor immunity, and systemic recom-
binant IL-9 therapy enhances tumor 
immunity. In addition, IL-9-producing 
Th9 cells are potent antitumor immune 
effector cells. On the basis of this 
work, Dr. Kupper suggested that ROR-γ 
blockade and IL-9/Th9 cell adoptive 
therapy may offer novel approaches 
for melanoma immuno therapy. Robert 
Fuhlbrigge (Harvard University, Boston, 
MA) described the effects of another IL 
molecule, IL-1, on cutaneous responses 
to vaccinia virus skin scarification. 
Studies with mice engineered to over-
express IL-1α demonstrated that IL-1 
enhances the adaptive immune response 
to vaccinia virus; in IL-1RI-null mice, 
however, vaccinia virus scarification 
resulted in larger skin lesions and sat-
ellite lesions. These mice exhibited 
virtually the same immune response 
that wild-type mice did, eventually 
producing clearance of the pathogen. 
Molecularly, deficiency of IL-1RI blocks 
signaling from IL-1α and IL-1β, which 
are both required for optimal local cuta-
neous response to vaccinia virus skin 
scarification. Thus, IL-1 appears to have 
a direct effect on the regulation of viral 
propagation in the skin and local tissues 
that is important early after infection and 
is distinct from induction of the adaptive 
immune response.
Skin disease etiology and treatment 
development
Understanding the etiology of skin dis-
eases ideally precedes the development 
of effective treatments. Epidermolysis 
bullosa (EB) is a group of blistering 
diseases that result from structural 
disruption of the dermal–epidermal 
junction (DEJ). Mei Chen (University 
of Southern California, Los Angeles) 
demonstrated that the type IV collagen 
binding site in the PCR3 subdomain of 
the noncollagenous domain 1 (NC1) 
of type VII collagen is a pathogenic 
epitope for EB acquisita (EBA) autoan-
tibodies. Antibodies to the PCR3 sub-
domain of NC1 raised in rabbits induce 
clinical, histological, and immunologi-
cal features of EBA in mice, and EBA 
autoantibodies abrogate the interac-
tions between this NC1 domain and 
type IV collagen. These results indicate 
that interactions between NC1 and 
type IV collagen may be critical for 
epidermal–dermal adherence and that 
disruption of this interaction by autoan-
tibodies may underlie the classic EBA 
phenotype of skin fragility, blisters, and 
minimal inflammation.
The William Montagna Lecture, which 
is intended to honor and reward young 
active investigators, was presented by 
John McGrath (King’s College London, 
UK). The focus of Dr. McGrath’s academ-
ic career has been the discovery of the 
etiology of inherited skin diseases, and 
his success has been enhanced through 
a series of global collaborations. In this 
lecture, Dr. McGrath described his work 
on the development of new therapies for 
EB based on the current understanding 
of the genotype–phenotype relationship 
paradigm. Indeed, a known spectrum 
of mutations in collagen VII, collagen 
XVII, keratin 14, keratin 5, plectin, lami-
nin, integrins, and bullous pemphigoid 
antigen 2 compromise the structure of 
the DEJ and result in a spectrum of phe-
notypes of EB. Exome sequencing has 
recently been successfully employed in 
cases where candidate gene approaches 
for diagnosis failed, because molecular 
genotyping for diagnosis offers impor-
tant information for treatment options, 
especially in newborns. New treatment 
modalities are desperately needed, and 
clinical trials of allogeneic fibroblasts 
in dystrophic EB have been initiated. A 
single injection of these cells results in 
increased collagen VII at the DEJ, and 
this collagen expression persists long 
after the transplanted cells are no longer 
identifiable. Transcriptomics revealed 
that heparin-binding epidermal growth 
factor-like growth factor is induced 
in this system and leads to increased 
expression of a mutant collagen VII that 
is partially functional. This expressed 
collagen ultimately leads to increased 
skin adhesion and correction of the 
defect.
Dr. McGrath also presented evi-
dence from collaborators in Chile in 
support of the use of subcutaneous 
injection of allogeneic bone marrow–
derived mesenchymal stem cells to 
heal blisters and increase collagen VII 
at the DEJ for treatment of recessive 
dystrophic EB (RDEB); however, bone 
marrow transplants seem mainly to 
restore the collagen VII–producing cells 
in the dermis and not to functionally 
correct the keratinocytes required for 
structural improvement. Finally, in col-
laboration with investigators in Japan, 
Dr. McGrath showed that a skin graft 
can act as a bioreactor to prime bone 
marrow–derived transplanted cells to 
regenerate the epidermis. This finding 
opens up new therapeutic possibilities 
for repairing the skin.
Jakub Tolar (University of Minnesota, 
Minneapolis) further described hema-
topoietic and mesenchymal stem cell 
treatment strategies for RDEB and junc-
tional EB. Adoptive transfer of bone 
marrow and cord blood cells resulted 
in functional correction of RDEB and 
junctional EB and yielded the benefits 
of allogeneic transplant without the side 
effects of such treatment. These results 
demonstrate the use of bone marrow 
transplantation for a disease that does 
not affect the blood but that requires 
corrected structural protein. Efforts to 
develop protocols for transplantation of 
collagen VII–corrected induced pluri-
potent stem cells for treatment of RDEB 
are under way.
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Cancer
In the EMBO Young Investigator Lecture, 
Cédric Blanpain (Interdisciplinary 
Research Institute, Brussels, Belgium) 
presented his work on defining the cell 
lineages at the origin of basal cell carci-
noma (BCC) and SCC. BCCs arise from 
dysregulation of Hedgehog (Hh) signal-
ing, with 80 to 90% of BCCs arising 
from loss of PTCH and the remaining 
10 to 20% arising from activating muta-
tions in the G-protein-coupled receptor 
Smoothened (SmoM2). Thus, targeting 
the Hh pathway activation in differ-
ent epidermal compartments allowed 
identification of the cellular origin of 
BCC. SmoM2 expression in the epider-
mis results in BCC, and clonal analysis 
revealed that the IF epidermis and the 
infundibulum, specifically long-term 
IF progenitors, lead to BCC develop-
ment, whereas activation of SmoM2 in 
HF stem cells does not. Similarly, dele-
tion of PTCH1 in the IF epidermis and 
the infundibulum induced BCC devel-
opment. In addition, BCCs have been 
shown to arise from HF stem cells and 
multiple epithelial progenitor popu-
lations in mice. The cellular origin of 
SCCs, which commonly result from 
mutations in the Ras pathway in both 
mice and humans, is somewhat contro-
versial because both HF bulge cells and 
IF cells can induce this malignancy. In 
continuation of this work, future stud-
ies will be directed at dissecting the 
molecular changes associated with skin 
cancer initiation.
In a presentation about the effects 
of chemotherapeutics on skin can-
cer, Ake Baibergenova (University of 
Toronto, Canada) reported that the 
results of the randomized multicenter 
chemoprevention trial (the VATTC trial) 
to investigate the onset of BCC and 
SCC are not consistent with a strong 
association between glucocorticoids, 
specifically oral prednisone use, and 
keratinocyte carcinoma in a popula-
tion of 1,051 non-transplant partici-
pants. In addition, Jean Tang (Stanford 
University) presented the results of a 
phase II randomized, double-blind, 
placebo-controlled trial of vismodegib 
(GDC-0499), a small-molecule inhibi-
tor of the Hh signaling pathway, for 
prevention of BCC in patients with 
basal cell nevus syndrome (BCNS). This 
drug works rapidly in BCNS patients to 
shrink existing BCCs and prevent new 
ones, with mild or moderate revers-
ible adverse effects. Unfortunately, the 
BCCs seem to return promptly after dis-
continuation of the drug, although no 
drug resistance was observed for the 
2,000 tumors analyzed.
Credited along with others with the 
discovery of p53, which is the most sig-
nificant of genes altered in cancer, Sir 
David Lane (Immunos, Singapore) gave 
the 2011 Naomi M. Kanof Lecture, 
which honors an individual who is 
making significant contributions to the 
improvement of health through clinical 
research. Dr. Lane described his work 
to bridge the bench and the bedside 
by optimizing the use of existing treat-
ments and developing new treatments 
for cancer. Because p53 functions to 
sense DNA damage and signal cell 
cycle arrest or apoptosis, its absence, 
not surprisingly, confers resistance to 
radiation and chemotherapy. Indeed, 
tumors with wild-type p53 are more 
sensitive to these therapies both in vitro 
and in vivo. These findings led to the 
speculation that tumors with wild-type 
p53 should be treated differently than 
those with mutant p53; however, diffi-
culties in both determining whether the 
p53 pathway is intact and teasing apart 
the p53-dependent and -independent 
actions of chemotherapeutic drugs 
make it hard to conduct clinical tri-
als testing this hypothesis. Thus, new 
p53 pathway–specific drugs are being 
pursued. Nutlin, which blocks the 
Mdm2–p53 interaction, induces apop-
tosis and G1 arrest only in cancer cells 
with wild-type p53, but in combina-
tion with VX-680 this drug appears to 
selectively kill p53-defective cells. In 
addition, a screen for selective inhibi-
tion of p53-deficient cells identified 
doxorubicin. This drug is currently 
under investigation for its use in treat-
ment of tumors with wild-type p53 
in combination with p21 inhibitors, 
tumors with p53 null mutations, and 
tumors with mutant p53 as well as for 
its contribution to tumor recurrence 
and resistance.
On the basis of her ongoing efforts 
to identify genes mutated in mela-
noma, Yardena Samuels (NHGRI, 
NIH) described her high-throughput 
mutational analysis of the cancer 
genome and subsequent functional 
analysis of the most highly mutated 
genes. Given the high number of new 
melanoma cases diagnosed each year 
and the poor prognosis for metastatic 
melanoma, the identification of genet-
ic alterations in these tumors may ulti-
mately provide new opportunities for 
drug development. Mutational analy-
sis of the tyrosine kinase family, which 
is frequently mutated in other cancer 
types and is particularly amenable to 
pharmacological targeting, revealed 
mutations in the receptor tyrosine pro-
tein kinase ERBB4 in melanoma. These 
mutations result in increased basal acti-
vation, and their presence sensitizes 
melanoma cells to lapatinib, a drug that 
has been approved by the US Food and 
Drug Administration for treating breast 
cancer. Furthermore, taking whole-
genome and whole-exome approaches 
based on new generation sequencing 
technology, this group identified nine 
novel genes (including TRRAP and 
GRIN2A), with recurring mutations, 
and the effects on these genes were 
further validated in functional assays. 
These studies have confirmed that a few 
gene alterations occur in the majority 
of cancers, but that a larger number of 
genes are mutated at a low frequency. 
Furthermore, the altered genes affect a 
limited number of cell signaling path-
ways. Currently, researchers are trying 
to apply these findings to the clinic by 
developing therapies targeted to these 
mutated factors or pathways for the 
treatment of melanoma.
In addition, a series of plenary 
presentations described the role of sev-
eral specific factors involved in skin 
tu morigenesis. Jiangli Chen (University 
of Colorado, Denver) demonstrated 
that the loss in surface epithelium of 
desmocollin 3 (DSC3), a core com-
ponent of desmosomes, causes skin 
blisters and promotes tumor formation. 
Furthermore, spontaneous DSC3 loss 
often occurs during tumor progression 
in mice and thus may serve as a 
marker for tumor progression. In addi-
tion, loss of DSC3 has been observed 
during tumor progression in human 
skin SCCs via a human skin cancer 
tissue array, highlighting the clini-
cal relevance of these investigations 
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in mice. Jin-Sung Chung (University 
of Texas Southwestern Medical 
Center, Dallas) presented evidence 
that mye loid-derived suppressor cells 
express DC-associated heparan sulfate 
proteoglycan-integrin ligand (DC-HIL), 
which binds to syndecan-4 on effector 
T cells to inhibit T-cell activation. Thus, 
DC-HIL is responsible for myeloid-
derived suppressor cell T-cell suppressor 
function, which promotes melanoma 
growth and metastasis. In fact, injec-
tion of an anti–DC-HIL antibody mark-
edly inhibited the growth of established 
melanomas, suggesting that DC-HIL is 
a potentially useful target for treating 
metastatic melanoma.
Finally, Scott Atwood (Stanford 
University) presented evidence that 
the canonical polarity protein atypical 
protein kinase C (aPKC ι/λ) regulates 
Hh signaling during BCC growth. This 
aPKC is upregulated in both mouse and 
human BCC and functions downstream 
of the Smo receptor to regulate cell 
polarity. Inhibition of the kinase activity 
of aPKC inhibits primary cilia and sup-
presses Hh signaling and BCC growth, 
offering a promising target for future 
BCC therapy. Clearly, identification of 
these crucial molecular players will be 
useful not only for understanding the 
mechanisms underlying skin cancer but 
also for developing critically needed 
therapies in the future.
Conclusions and a comment  
about mentoring
The Annual Meeting of the SID brought 
together clinicians, basic researchers, 
students, residents, and postdoctoral 
fellows to exchange ideas in the broad 
fields of dermatology and cutaneous 
biology. In concert with the associated 
group meetings, symposia, and clinical 
and translational research track pro-
gramming, the scientific program offered 
researchers from the international 
dermatology community an opportu-
nity to share their cutting-edge research 
and to foster collaborations to further 
the field of basic skin biology and skin 
disease. Within this context, important 
aspects of mentoring—the theme of the 
Journal of Investigative Dermatology for 
2011—were clearly visible through-
out the meeting. Mentors and mentees 
met in the hallways, conferred in the 
restaurants, and offered advice in the 
poster exhibits, and this exchange was 
a thrilling process to observe. With an 
international community of more than 
1,500 attendees, this forum success-
fully melded basic science, clinical 
applications, and career development 
to advance and promote the dermato-
logic sciences.
*The 71st Annual Meeting of the Society for 
Investigative Dermatology (SID) was held at 
the JW Marriott Desert Ridge Resort & Spa in 
Phoenix, Arizona, 4–7 May 2011.
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